GenSpera Inc. – “Glioblastoma Trial Design”

NEW YORK, NY / ACCESSWIRE / May 14, 2015 / GenSpera Inc. (OTCQB: GNSZ) today published a new blog post on The Chairman’s Blog, written by the Company’s chief executive officer, Craig Dionne, Ph.D. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.

Mr. Dionne discusses how the pharmaceutical industry designs and conducts clinical trials under FDA oversight in his latest blog, addressing what the expansion of the Phase II study in patients with glioblastoma means for mipsagargin and the Company. “Not only does this transition indicate sufficient reason to move forward with the study, it also indicates that mipsagargin is well-tolerated in this patient population,” explained Dionne. Read the full blog post from Dr. Craig Dionne on TheChairmansBlog.com (http://www.thechairmansblog.com/genspera/craig-dionne/glioblastoma-trial-design/).

About GenSpera

GenSpera Inc. is a San Antonio-based biotech company that unlocks conventional thinking to conceive, design, and develop cancer therapies. GenSpera’s technology platform combines a powerful, plant-derived cytotoxin (thapsigargin) with a patented prodrug delivery system that provides for targeted release of drug candidates within tumors. GenSpera’s lead drug candidate, mipsagargin, was granted Orphan Drug designation by the U.S. Food and Drug Administration (FDA) in 2013 for evaluation in patients with hepatocellular carcinoma (liver cancer).

For additional information on GenSpera, visit www.genspera.com and connect on Twitter, LinkedIn, Facebook, YouTube and Google+.

About TheChairmansBlog.com

TheChairmansBlog.com is an exclusive, online media publication where publicly and privately held firms alike share insights about their companies and industries. TheChairmansBlog.com enables upper tier management to discuss issues that are of importance to their stakeholders, shareholders, and interested parties in an informal environment. www.thechairmansblog.com

SOURCE: TheChairmansBlog.com

ReleaseID: 428897